Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: TATRADER who wrote (737)	6/4/1998 9:30:00 AM
From: majormember	Read Replies (1) \| Respond to of 59879

SNRS Management...I e-mailed CFO on your and other peoples concerns over current trend and Nasdaq listing issue...Regards, Skane ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ April 24, 1998 Letter from the President Sunrise is a company with a new mission, new and experienced management, and results that begin to reflect our assertive move into the field of refractive surgery. Our aspirations exceed what we have accomplished thus far at Sunrise, but evidence suggests we are heading in the right direction. Our goal is to revolutionize the treatment of hyperopia by providing a technology that delights both patients and ophthalmic surgeons. To accomplish this we strive to optimize clinical results, treatment time, and economic issues and opportunities for these two key customer groups. In 1997 the new Sunrise Technologies became a compelling challenger in the emerging ophthalmic refractive surgery industry. The resulting valuation for Sunrise, after the divestiture of our dental business, was positive as our new focused strategy was greeted by the investment community with a strong increase in our stock price during the calendar year. Jeffries and Company, a leading investment bank that tracks data regarding stock performance on 247 medical device companies, published data that shows our company experienced an increase in stock price of 292.9% in 1997. This represents the 3rd highest percentage increase of the 247 companies followed. Relevant data from Jeffries and Company shows the following: Sunrise Technologies Up 292.9 % S & P 400 Up 28.9 % Medical Device Index Average Up 7.0 % Large Cap Medical Device Average Up 27.0 % Mid Cap Medical Device Average Up 18.5 % Small Cap Medical Device Average Up 5.1 % Micro Cap Medical Device Average Up 4.5 % Ophthalmic Medical Device Average Up 41.1 % Our performance exceeded every average in each index while finishing #1 in ophthalmics (out of 12 companies), #2 in Micro Caps (out of 99 companies) and #3 overall (out of 247 companies). The focus in 1997 was in four key areas: new people, new funds to finance our company, new product development, and new results from our clinical studies in treating hyperopia and presbyopia. New people are in charge of all major departments at Sunrise since I joined the Company in mid-1996. Our senior management team has decades of experience in the ophthalmology business and all of them have joined Sunrise since my arrival. Their achievements have been noteworthy. In addition, three new members were added to the Board of Directors: Timothy A. Marcotte, Sunrise's Vice President of Finance and Chief Financial Officer, R. Dale Bowerman, former CEO of Firstcare Southwest Health Alliances, and Dr. Michael S. McFarland, winner of the "Innovators Award" for his development of sutureless cataract surgery from the Irish American Ophthalmological Society. New funds in the amount of $17.0 million were raised between January 1, 1997 and the writing of this letter, including the proceeds from the sale of the dental business in June 1997. This money should allow us to finish the current hyperopia clinical trial and fund normal business expenses to the year 2000. New product development targeted at creating a modern, robust, enhanced laser for treating hyperopia moved at a very brisk pace in 1997. Feedback from our prestigious Scientific Advisory Board is being incorporated in our new laser that we plan to launch in the United States once we receive approval to market from the FDA. New results from our clinical study continue to be generated. Our all-star group of clinical investigators headed by Medical Monitor, Dr. Douglas D. Koch, treated enough patients with such good results that we received approval from FDA to enter the third and final phase of our clinical trial for hyperopia. It is our belief that a new, positive relationship has been established between Sunrise and the FDA and we look forward to continued success in our clinical trials. The new Sunrise is committed to giving our customers a revolutionary technology that we hope will change the way hyperopia is treated. We look forward to serving them in a way that brings increased value to our shareholders. Sincerely, C. Russell Trenary III President & CEO